Gabapentin Tablet
Product Images NDC 68788-8476

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68788-8476). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin Tablets 600mg (38119f2e 33b3 4c3c 99b7 9335d8d280d4 00)

Packaging label for Gabapentin Tablets 600 mg, a human prescription oral tablet manufactured by Preferred Pharmaceuticals Inc. The label includes directions for use in both English and Spanish, a barcode, and cautions about federal law prohibiting transfer of the drug. It states the product is generic for Neurontin and notes storage temperature details.*

FDA Label Image

Sideeffects (Sideeffects)

A text panel listing potential side effects or symptoms related to a medication. The list includes lack of coordination, viral infection, difficulty with speaking, tremor, swelling usually of legs and feet, feeling tired, fever, feeling drowsy, nausea and vomiting, jerky movements, difficulty with coordination, double vision, and unusual eye movement.*

FDA Label Image

Table-1 (Table1)

A table titled 'Gabapentin Dosage Based on Renal Function' showing dosage guidance for gabapentin tablets based on renal function measured by creatinine clearance (mL/min). It lists total daily dose ranges (mg/day) and corresponding dose regimens (mg) for different renal function categories, including supplemental post-hemodialysis doses. Footnotes clarify dosage adjustments for patients with low creatinine clearance and hemodialysis considerations.*

FDA Label Image

Table-2 (Table2)

A data table titled 'Risk by Indication for Antiepileptic Drugs in the Pooled Analysis' comparing placebo and drug patients. It lists incidences of events per 1,000 patients across indications including Epilepsy, Psychiatric, Other, and Total. Columns show placebo and drug patient event rates, relative risk, and risk difference per 1,000 patients.*

FDA Label Image

Table-3 (Table3)

A data table titled 'Adverse Reactions in Pooled Placebo-Controlled Trials in Postherpetic Neuralgia' comparing the percentage incidences of various adverse reactions between Gabapentin (N=336) and placebo (N=227) groups. It categorizes reactions by body system including body as a whole, digestive, metabolic, nervous, respiratory, and special senses, listing specific symptoms and their respective occurrence percentages.*

FDA Label Image

Table-4 (Table4)

Table presenting adverse reactions in pooled placebo-controlled add-on trials in epilepsy patients aged over 12, comparing Gabapentin (N=543) and placebo (N=378). It categorizes side effects by body systems such as body as a whole, cardiovascular, digestive, nervous, respiratory, skin, urogenital, and special senses, with percentage incidences for each treatment group.*

FDA Label Image

Table-5 (Table5)

A data table titled 'Adverse Reactions in a Placebo-Controlled Add-On Trial in Pediatric Epilepsy Patients Age 3 to 12 Years' comparing adverse reaction percentages between Gabapentin (N=119) and placebo (N=128) groups. Categories include Body as a Whole, Digestive System, Nervous System, and Respiratory System with specific reactions such as viral infection, fever, somnolence, and bronchitis.*

FDA Label Image

Table-6 (Table6)

A data table titled 'Controlled PHN Studies: Duration, Dosages, and Number of Patients' showing two studies with their durations in weeks, gabapentin target doses in mg/day, number of patients receiving gabapentin, and number receiving placebo. Study 1 lasted 8 weeks with a gabapentin dose of 3600 mg/day and Study 2 lasted 7 weeks with doses of 1800 and 2400 mg/day. Total patients were 336 for gabapentin and 227 for placebo.*

FDA Label Image

Clcr (Clcr)

An illustration depicting the formula for calculating creatinine clearance (CLCr), showing the relationship between age, weight, serum creatinine, and a gender adjustment factor for female patients.*

FDA Label Image

Figure-1 (Figure1)

A line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 1' showing mean pain scores on the y-axis (0 to 10) and weeks on the x-axis (Baseline to 8 weeks). Two lines represent placebo and gabapentin 3600 mg/day groups, with gabapentin consistently showing lower mean pain scores over the 8-week period including dose titration and fixed dose phases.*

FDA Label Image

Figure-2 (Figure2)

A line graph showing weekly mean pain scores over 7 weeks in a study population. The x-axis represents the weeks, starting from Baseline to Week 7, and the y-axis shows the mean pain score from 0 to 10. Three lines compare placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day during a 3-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Figure-3 (Figure3)

A bar chart titled 'Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies.' It compares responder proportions in two studies, showing percentages for placebo (PBO) and gabapentin (GBP) at different dosages (3600 mg, 1800 mg, 2400 mg). The chart highlights statistically significant differences marked by asterisks (p <0.01 and p <0.001).*

FDA Label Image

Figure-4 (Figure4)

A chart showing responder rates in patients receiving gabapentin compared to placebo by daily dose in mg, based on three adjunctive therapy studies in patients aged 12 years or older with partial seizures. The vertical axis shows difference in percentage, and the horizontal axis shows daily gabapentin dose ranging from 600 to 1800 mg. Data points are labeled for three separate studies.*

FDA Label Image

Struc (Struct)

Chemical structure of gabapentin, showing a cyclohexane ring attached to a carbon bonded to both an amino group and a carboxyl group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.